Improving oral delivery

Handbook of Experimental Pharmacology

Volumn 197, Issue , 2010, Pages 345-398

  Gabor, Franz ^a   Fillafer, Christian ^b   Neutsch, Lukas ^b   Ratzinger, Gerda ^b   Wirth, Michael ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Absorption enhancer; Biorecognition; Delayed release; Enzyme mediated release; Floating delivery systems; G I physiology; Gastroretentive; Hydrogel; Microparticle; Nanoparticle; Osmotic pump; PH dependent release; Targeting

Indexed keywords

APREPITANT; BENSERAZIDE PLUS LEVODOPA; BUDENOFALK; BUDESONIDE; CAPTOPRIL; CHITOSAN; CIPROFLOXACIN; DIAZEPAM; DILTIAZEM; DOXAZOSIN; ETHYL CELLULOSE; EUDRAGIT; FENOFIBRATE; GLIPIZIDE; HYDROXYPROPYLMETHYLCELLULOSE; MEGACE ES; MEGESTROL ACETATE; MESALAZINE; METHYLPHENIDATE; METOPROLOL; MISOPROSTOL; NANOPARTICLE; NIFEDIPINE; PALIPERIDONE; PHENYLPROPANOLAMINE; PIRETANIDE; POLYGLACTIN; RAPAMYCIN; TOLBUTAMIDE; TRIGLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; DRUG;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SOLUBILITY; ENZYME ACTIVITY; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; HUMAN; HYDROGEL; INTESTINE CELL; MICROFLUIDICS; NANOTECHNOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; OSMOTIC PRESSURE; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; STOMACH PH; CHEMISTRY; METABOLISM; METHODOLOGY; PERMEABILITY; PH;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; HUMANS; HYDROGEN-ION CONCENTRATION; OSMOTIC PRESSURE; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS;

EID: 77953258460     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-00477-3_12     Document Type: Review

References (202)

1. Ahmed IS (2005) Effect of simulated gastrointestinal conditions on drug release from pectin/ ethylcellulose as film coating for drug delivery to the colon. Drug Dev Ind Pharm 31:465-470
2. Aikawa K, Matsumoto K, Uda H, Tanaka S, Shimamura H, Aramaki Y, Tsuchiya S (1998) Hydrogel formation of the pH response polymer polyvinylacetal diethylaminoacetate (AEA). Int J Pharm 167:97-104
3. Akala EO, Kopeckova P, Kopecek J (1998) Novel pH-sensitive hydrogels with adjustable swelling kinetics. Biomaterials 19:1037-1047
4. Allen A (1984) The structure and function of gastrointestinal mucus. In: Boedeker EC (ed) Attachment of organisms to the gut mucosa. CRC, Boca Raton, FL, pp 4-10
5. Amidon GL, Lennernäs H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation in-vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420
6. Anal AK (2007) Time-controlled pulsatile delivery systems for bioactive compounds. Recent Pat Drug Deliv Formul 1:73-79
7. Anton N, Benoit JP, Saulnier P (2008) Design and production of nanoparticles formulated from nano-emulsion templates - A review. J Control Release 128:185-199
8. Arora S, Ali J, Ahuja A, Khar RK, Baboota S (2005) Floating drug delivery systems: a review. AAPS PharmSciTech 6:E372-E390
9. Asghar LFA, Chandran S (2006) Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharm Sci 9:327-338
10. Aungst BJ (2000) Intestinal permeation enhancers. J Pharm Sci 89:429-442
11. Aziz MA, Midha S, Waheed SM, Bhatnagar R (2007) Oral vaccines: new needs, new possibilities. Bio Essays 29:591-604
12. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F (2006) Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release 111:1-18
13. Bar-Shalom D, Bukh M, Kindt Larsen T (1991) Egalet1, a novel controlled-release system. Ann NY Acad Sci 618:578-580
14. Basak P, Adhikari B (2008) Poly (vinyl alcohol) hydrogels for pH dependent colon targeted drug delivery. J Mater Sci Mater Med. doi:10.1007/s10856-008-3496-0
15. Bernkop-Schnürch A (2005) Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev 57:1569-1582
16. Bonnet MC, Dutta A (2008) World wide experience with inactivated poliovirus vaccine. Vaccine 26:4978-4983
17. Borm P, Klaessig FC, Landry TD, Moudgil B, Pauluhn J, Thomas K, Trottier R, Wood S (2006) Research strategies for safety evaluation of nanomaterials, Part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicol Sci 90:23-32
18. Bourgeois S, Harvey R, Fattal E (2005) Polymer colon drug delivery systems and their application to peptides, proteins, and nucleic acids. Am J Drug Deliv 3:171-204
19. Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25:5467-5484
20. Brandtzaeg P, Halstensen TS, Kett K, Krajci P, Kvale D, Rognum TO, Scott H, Sollid LM (1989) Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterol 97:1562-1584
21. Brayden DJ (2001) Oral vaccination in man using antigens in particles: current status. Eur J Pharm Sci 14:183-189
22. Brayden DJ, Baird AW (2001) Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes Infect 3:867-876
23. Brayden DJ, Jepson MA, Baird AW (2005) Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov Today 10:1145-1157
24. Brockmeier D, Grigoleit HG, Leonhardt H (1986) The absorption of piretanide from the gastrointestinal tract is site-dependent. Eur J Clin Pharmacol 30:79-82
25. Brondsted H, Kopecek J (1992) Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm Res 9:1540-1545
26. Brown SR, Cann PA, Read NW (1990) Effect of coffee on distal colon function. Gut 31:450-453
27. Brunner E (1904) Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. Z Phys Chem 47:56-102
28. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE (1983) Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 28:609-615
29. Chawla G, Gupta P, Koradia V, Bansal AK (2003) Gastroretention - a means to address regional variability in intestinal drug absorption. Pharm Technol 27:50-68
30. Chen SC, Wu YC, Mi FL, Lin YH, Yu LC, Sung HW (2004) A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery. J Control Release 96:285-300
31. Chen X, Young TJ, Sarkari M, Williams III RO, Johnston KP (2002) Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm 242:3-14
32. Chiu HC, Hsiue GH, Lee YP, Huang LW (1999) Synthesis and characterization of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system. J Biomater Sci Polym Ed 10:591-608
33. Chourasia MK, Jain SK (2004) Polysaccharides for colon targeted drug delivery. Drug Deliv 11:129-148
34. Clark MA, Hirst BH, Jepson MA (1998) M-cell surface beta 1 integrin expression and invasinmediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells. Infect Immun 66:1237-1243
35. Colombo P, Santi P, Bettini R, Brazel CS (2000) Drug release from swelling-controlled systems. In: Wise DL (ed) Handbook of pharmaceutical controlled release technology. Marcel Dekker, New York, pp 183-209
36. Conley R, Gupta SL, Sathyan G (2006) Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 22:1879-1892
37. Constantinides PP, Welzel G, Smith EH, PL SS, Yiv SH, Owen AB (1996) Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation. Pharm Res 13:210-215
38. Crevoisier C, Hoevels B, Zurcher G, Da Prada M (1987) Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol 27:36-46
39. Davis ME, Brewster ME (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3:1023-1035
40. Davis SS, Khosla R, Wilson CG, Washington N (1987) The gastrointestinal transit of a controlled release pellet formulation of tiaprofenic acid. Int J Pharm 34:253-258
41. Debongie JC, Philips SF (1978) Capacity of the human colon to absorb fluid. Gastroenterology 74:698-703
42. Delie F, Blanco-Prieto MJ (2005) Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10:65-80
43. Dearn AR (1997) Atovaquone pharmaceutical compositions. US6018080
44. des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116:1-27
45. Dressman JB (1986) Comparison of canine and human gastrointestinal physiology. Pharm Res 3:123-131
46. Edsbäcker S, Bengtsson B, Larsson P, Lundin P, Nilsson A, Ulmius J, Wollmer P (2003) A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 17:525-536
47. Edwards C (1997) Physiology of the colorectal barrier. Adv Drug Deliv Rev 28:173-190
48. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL (2000) Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 198:239-247
49. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD (1988) Measurement of gastrointestinal pH profiles in normal, ambulant human subjects. Gut 29:1035-1041
50. Fasano A, Uzzau S (1997) Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 99:1158-1164
51. Fedorak RN, Bistritz L (2005) Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 57:303-316
52. Feldman M, Barnett C (1991) Fasting gastric pH and its relationship to true hypochlorhydria in humans. Dig Dis Sci 36:866-869
53. Fillafer C, Friedl DS, Wirth M, Gabor F (2008) Fluorescent bio-nanoprobes to characterise cytoadhesion and cytoinvasion. Small 4:627-633
54. Florence AT (1997) The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 14:259-266
55. Florence AT (2005) Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discov Today Technol 2:75-81
56. Florence AT (2006) Nanoparticle flow: implications for drug delivery. In: Torchilin VP (ed) Nanoparticles as drug carriers. Imperial College Press, London, pp 9-27
57. Florence AT, Attwood D (2006) Physicochemical principles of pharmacy, 4th edn. Pharmaceutical Press, London, Chicago
58. Foster N, Hirst BH (2005) Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv Drug Deliv Rev 57:431-450
59. Foxwell AR, Cripps AW, Kyd JM (2007) Optimization of oral immunization through receptormediated targeting of M cells. Hum Vaccin 3:220-223
60. Friend DR (2005) New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev 57:247-265
61. Friend DR, Chang GW (1984) A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem 27:261-266
62. Gabius HJ (2000) Biological information transfer beyond the genetic code: the sugar code. Naturwissenschaften 87:108-121
63. Gabor F, Bogner E, Weissenböck A, Wirth M (2004) The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev 56:459-480
64. Galli C (2006) Experimental determination of the diffusion boundary layer width of micron and submicron particles. Int J Pharm 313:114-122
65. Gallo SH, McClave SA, Makk LJK, Looney SW (1996) Standardization of clinical criteria required for use of the 12.5mm barium tablet in evaluating esophageal lumenal patency. Gastrointest Endosc 44:181-184
66. Gazzaniga A, Palugan L, Foppoli A, Sangalli ME (2008) Oral pulsatile delivery systems based on swellable hydrophilic polymers. Eur J Pharm Biopharm 68:11-18
67. Gazzaniga A, Sangalli ME, Giordano F (1994) Oral chronotopic1 drug delivery systems: achievement of time and/or site specificity. Eur J Pharm Biopharm 40:246-250
68. Gohil JM, Bhattacharya A, Ray P (2006) Studies on the cross-linking of poly (vinyl alcohol). J Polym Res 13:161-169
69. Gould S, Scott RC (2005) 2-Hydroxypropyl-b-cyclodextrin (HP-b-CD): a toxicology review. Food Chem Toxicol 43:1451-1459
70. Gupta VS, Beckert TE, Price JC (2001) A novel pH- and time-based multi-unit potential colonic drug delivery system. Int J Pharm 213:83-91
71. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, Langguth P (2007) Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev 59:419-426
72. Harder S, Fuhr U, Beermann D, Staib AH (1990) Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with hf-capsule. Br J Clin Pharmacol 30:35-39
73. Hardy JG, Evans DF, Zaki I, Clark AG, Tonnesen HH, Gamst ON (1987) Evaluation of an enteric-coated naproxen tablet using gamma scintigraphy and pH monitoring. Int J Pharm 37:245-250
74. Hardy JG, Wilson CG, Wood E (1985) Drug delivery to the proximal colon. J Pharm Pharmacol 37:874-877
75. Hastewell J, Lynch S, Fox R, Williamson I, Skelton-Stroud P, Mackay M (1994) Enhancement of human calcitonin absorption across the rat colon in vivo. Int J Pharm 101:115-120
76. Havgaard L, Brondsted H (1996) Current applications of polysaccharides in colon targeting. Crit Rev Ther Dug Carrier Syst 13:185-223
77. Hejazi R, Amiji M (2003) Chitosan-based gastrointestinal delivery systems. J Control Release 89:151-165
78. Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL (1995) Asymmetric-membrane tablet coatings for osmotic drug-delivery. J Control Release 35:127-136
79. Houghton LA, Mangnall YF, Read NW (1990) Effect of incorporating fat into a liquid test meal on the relation between intragastric distribution and gastric emptying in human volunteers. Gut 31:1226-1229
80. Hu J, Johnston KP, Williams RO (2003) Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur J Pharm Sci 20:295-303
81. Hu M, Amidon GL (1988) Passive and carrier mediated intestinal absorption components of captopril. J Pharm Sci 77:1007-1011
82. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT (2002) A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 91:1991-2002
83. Hussar DA (2000) Tablet-splitting games are bad patient care ... and bad pharmacy practice. Pharm Today 6:5
84. Hwang SJ, Park H, Park K (1998) Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 15:243-284
85. Ichikawa M, Watanabe S, Miyake Y (1991) A new multiple-unit oral floating dosage system. I: preparation and in vitro evaluation of floating and sustained-release characteristics. J Pharm Sci 80:1062-1066
86. Jani P, Halbert GW, Langridge J, Florence AT (1990) Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 42:821-826
87. Jani PU, Florence AT, McCarthy DE (1992) Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int J Pharm 84:245-252
88. Jobin G, Cortot A, Godbillon I, Duval M, Schoeller JP, Hirtz J, Bernier JJ (1985) Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Br J Clin Pharmacol 19:975-1055
89. Kararli TT (1989) Gastrointestinal absorption of drugs. Crit Rev Ther Drug Carrier Syst 6:39-86
90. Katsuma M, Watanabe S, Kawai H, Takemura S, Masuda Y, Fukui M (2002) Studies on lactulose formulations for colon-specific drug delivery. Int J Pharm 249:33-43
91. Keck CM, Müller RH (2006) Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62:3-16
92. Kesisoglou F, Panmai S, Wu Y (2007) Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59:631-644
93. Kimura K, Hirayama F, Uekama K (1999) Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior. Int J Pharm 88:385-391
94. King LS, Lozono D, Agre P (2004) From structure to disease: the evolving tale of aquaporin biology. Nat Rev Mol Cell Biol 5:687-698
95. Kirwan WO, Smith AN (1974) Gastrointestinal transit estimated by an isotope capsule. Scand J Gastroenterol 9:763-766
96. Klausner EA, Lavy E, Friedman M, Hoffman A (2003) Expandable gastroretentive dosage forms. J Control Release 90:143-162
97. Kompella UB, Lee VHL (2001) Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev 46:211-245
98. Krause KP, Kayser O, Mäder K, Gust R, Müller RH (2000) Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int J Pharm 196:169-172
99. Krishnamachari Y, Madan P, Lin S (2007) Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 338:238-247
100. Kumar RMN (2000) Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 3:234-258
101. Lamprecht A, Schaefer U, Lehr CM (2001) Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 18:788-793
102. Langguth P, Fricker G, Wunderli-Allenspach H (2004) Biopharmazie. Wiley, Weinheim, p 180 Chapter 5
103. Larsen C, Jensen BH, Olesen HP (1991) Stability of ketoprofen-dextran ester prodrugs in homogeneates of various segments of the pig GI tract. Acta Pharm Nord 3:41-44
104. Lennernäs H, Abrahamsson B (2005) The use of biopharmaceutic classification of drugs in drug discovery and development: current stauts and future extension. J Pharm Pharmacol 57:273-285
105. Levine MM (2003) Can needle-free administration of vaccines become the norm in global immunization? Nat Med 9:99-103
106. Lin CC, Metters AT (2006) Hydrogels in controlled release formulations: network design and mathematical modeling. Adv Drug Deliv Rev 58:1379-1408
107. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26
108. Lipton JR, Coder DM, Jacobs LR (1988) Longterm effects of fermentable fibres on rat colonic pH and epithelial cell cycle. J Nutr 118:840-845
109. Liu L, Ku J, Khang G, Lee B, Rhee JM, Lee HB (2000) Nifedipine controlled delivery by sandwiched osmotic tablet system. J Control Release 68:145-156
110. Liversidge GG, Cundy KC (1995) Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125:91-97
111. Lochner N, Pittner F, Wirth M, Gabor F (2003) Wheat germ agglutinin binds to the epidermal growth factor-receptor of artificial Caco-2 membranes as detected by silver nanoparticle enhanced fluorescence. Pharm Res 20:833-839
112. Lorenzo-Lamosa ML, Remunan-Lopez C, Vila-Jato JL, Alonso MJ (1998) Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release 52:109-118
113. Lui CY, Amidon GL, Berardi RR (1986) Comparison of gastrointestinal pH in dogs and humans: implications of the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 75:271-274
114. Mackay M, Phillips J, Hastewell J (1997) Peptide drug delivery: colonic and rectal absorption. Adv Drug Deliv Rev 28:253-273
115. Mayo-Pedrosa M, Cachafeiro-Andrade N, Alvarez-Lorenzo C, Martinez-Pacheco R, Concheiro A (2008) In situ photopolymerization-coated pellets for pH-dependent drug delivery. Eur Polymer J 44:2626-2638
116. McNeil NI, Ling KLE, Wager J (1987) Mucosal surface pH of the large intestine of the rat and of normal and inflamed large intestine in man. Gut 28:707-713
117. Melander A (1987) Influence of food on the bioavailability of drugs. Clin Pharmacokinet 3:337-341
118. Merisko-Liversidge E, Liversidge GG, Cooper ER (2003) Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18:113-120
119. Metcalf AM, Phillips SF, Zinsmeister AR, Mac-Carthy RL, Beart RW, Wolff BG (1987) Simplified assessment of segmental colonic transit. Gastroenterology 91:40-47
120. Miller H, Zhang J, KuoLee R, Patel GB, Chen W (2007) Intestinal M cells: the fallible sentinels? World J Gastroenterol 13:1477-1486
121. Milojevic S, Newton JM, Cummings JH, Gibson GR, Botham RL, Ring SG, Stockham M, Allwood MC (1996) Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J Control Release 38:75-84
122. Minami K, Hirayama F, Uekama K (1998) Colon-specific drug delivery based on a cyclodextrin prodrug: release behaviour of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J Pharm Sci 87:715-720
123. Minko T (2004) Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 56:491-509
124. Möschwitzer J, Müller RH (2007) Drug nanocrystals - the universal formulation approach for poorly soluble drugs. In: Thassu D, Deleers M, Pathak Y (eds) Nanoparticulate Drug Delivery Systems. Informa Healthcare, New York, pp 71-88
125. Mountfield RJ, Senepin S, Schleimer M, Walter I, Bittner B (2000) Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm 211:89-92
126. Moustafine RI, Kabanova TV, Kemenova VA, Van Den Mooter G (2005) Characteristics of interpolyelectrolyte complexes of Eudragit E100 with Eudragit L100. J Control Release 103:191-198
127. Muranushi N, Takagi S, Muranishi S, Sezaki H (1981) Effect of fatty acids and monoglycerides on permeability of lipid bilayer. Chem Phys Lipids 28:269-279
128. Müller RH, Peters K (1998) Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm 160:229-237
129. Nernst W (1904) Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. Z Phys Chem 47:52-55
130. Nerurkar MM, Burton PS, Borchardt RT (1996) The use of surfactants to enhance the permeability of peptides through caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 13:528-534
131. Noyes AA, Whitney WR (1897) The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934
132. O'Hagan DT, Singh M, Ulmer JB (2006) Microparticle-based technologies for vaccines. Methods 40:10-19
133. Ozeki Y, Ando M, Watanabe Y, Danjo K (2004) Evaluation of novel one-step dry-coated tablets as a platform for delayed-release tablets. J Control Release 95:51-60
134. Patel VR, Amiji MM (1996) Preparation and characterization of freeze-dried chitosan-poly (ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach. Pharm Res 13:588-593
135. Peek LJ, Middaugh CR, Berkland C (2008) Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 60:915-928
136. Peppas LB, Peppas NA (1990) Dynamic and equilibrium swelling behaviour of pH-sensitive hydrogels containing 2-hydroxyethyl methacrylate. Biomaterials 11:635-644
137. Peppercorn MA (1984) Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development. Ann Int Med 101:377-386
138. Perrie Y, Kirby D, Bramwell VW, Mohammed AR (2007) Recent developments in particulatebased vaccines. Recent Pat Drug Deliv Formul 1:117-129
139. Porter CJH, Pouton CW, Cuine JF, Charman WN (2008) Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 60:673-691
140. Qiu Y, Park K (2001) Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 53:321-339
141. Rasenack N, Hartenhauer H, Müller BW (2003) Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int J Pharm 254:137-145
142. Read NW, Miles CA, Fisher D, Holgate AM, Kime ND, Mitchell MA, Reeve AM, Walker W (1980) Transit of a meal through the stomach, small intestine and colon of normal subjects and its role in the pathogenesis of diarrhea. Gastroenterology 79:1276-1282
143. Roth-Walter F, Schoell I, Untersmayr E, Fuchs R, Boltz-Nitulescu G, Weissenboeck A, Scheiner O, Gabor F, Jensen-Jarolim E (2004) M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J Allergy Clin Immunol 114:1362-1368
144. Roth-Walter F, Bohle B, Schoell I, Untersmayr E, Scheiner O, Boltz-Nitulescu G, Gabor F, Brayden DJ, Jensen-Jarolim E (2005a) Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. Immunol Lett 100:182-188
145. Roth-Walter F, Schoell I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E (2005b) Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 23:2703-2710
146. Roth-Walter F, Jensen-Jarolim E (2007) Oral immunotherapy against type I allergy. J Allergy Clin Immunol 19:21-26
147. Rouge N, Buri P, Doelker E (1996) Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 136:117-139
148. Rubinstein A, Nakar D, Sintov A (1992) Chondroitin-sulfate: a potential biodegradable carrier for colon-specific drug delivery. Int J Pharm 84:141-150
149. Rubinstein A, Tirosh B, Baluom M, Nassar T, David A, Radai R, GlikoKabir I, Friedman M (1997) The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. J Control Release 46:59-73
150. Russell-Jones GJ, Arthur L, Walker H (1999) Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. Int J Pharm 179:247-255
151. Salama NN, Eddington ND, Fasano A (2006) Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 58:15-28
152. Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga A (2001) In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J Control Release 73:103-110
153. Scheline RR (1973) Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 25:451-523
154. Schiller C, Fröhlich CP, Giessmann T, Siegmund W, Moennikes H, Hosten N, Weitschies W (2005) Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonace imaging. Aliment Pharmacol Ther 22:971-979
155. Shakweh M, Ponchel G, Fattal E (2004) Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv 1:141-163
156. Sharon N, Lis H (2004) History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 14:53R-62R
157. Shokri J, Ahmadi P, Rashidi P, Shahsavari M, Rajabi-Siahboomi A, Nokhodchi A (2008) Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs. Eur J Pharm Biopharm 68:289-297
158. Siegel RA, Falamarzian BA, Firestone BA, Moxley BC (1988) pH-controlled release from hydrophobic/polyelectrolyte co-polymer hydrogels. J Control Release 8:179-182
159. Simpkins JW, Smulkowski M, Dixon R, Tuttle R (1988) Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Phamacol Exp Ther 244:195-205
160. Singh BN, Kim KH (2000) Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 63:235-259
161. Sinha VR, Kumria R (2003) Microbially triggered drug delivery to the colon. Eur J Pharm Sci 18:3-18
162. Smart JD (2005) Buccal drug delivery. Expert Opin Drug Deliv 2:507-517
163. Smith GW, Wiggins PM, Lee SP, Tasman-Jones C (1986) Diffusion of butyrate through pig colon mucus in vitro. Clin Sci 70:271-276
164. Sood A, Panchagnula R (2001) Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev 101:3275-3303
165. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H (2007) When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci 31:249-261
166. Streubel A, Siepmann J, Bodmeier R (2006) Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol 6:501-508
167. Strickley RG (2004) Solubilizing excipients in oral and injectable formulations. Pharm Res 21:201-230
168. Swaan PW, Szoka FC, Oie S (1996) Use of the intestinal and hepatic bile acid transporters for drug delivery. Adv Drug Deliv Rev 20:59-82
169. Takeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39-54
170. Talukder R, Fassihi R (2004) Gastroretentive delivery systems: a mini review. Drug Dev Ind Pharm 30:1019-1028
171. Tang R, Orme CA, Nancollas GH (2004) Dissolution of crystallites: surface energetic control and size effects. Chem Phys Chem 5:688-696
172. Terwogt MJM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JHM (1998) Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352:285
173. Thomas E, Rubino J (1996) Solubility, melting point and salting-out relationships in a group of secondary amine hydrochloride salts. Int J Pharm 130:179-183
174. Thombre AG, Appel LE, Chidlaw MB, Daugherity PD, Dumont F, Evans LAF, Sutton SC (2004) Osmotic drug delivery using swellable-core technology. J Control Release 94:75-89
175. Thombre AG, Cardinal JR, DeNoto AR, Herbig SM, Smith KL (1999) Asymmetric membrane capsules for osmotic drug delivery. I. Development of a manufacturing process. J Control Release 57:55-64
176. Tugcu-Demiroz F,Acartürk F, Takka S,Konus-Boyunaga O(2004) In-vitro and in-vivo evaluation of mesalazine-guar gum matrix tablets for colonic drug delivery. J Drug Target 12:105-112
177. Van den Mooter G, Samyn C, Kinget R (1992) Azo polymers for colon-specific drug delivery. Int J Pharm 87:37-46
178. Van den Mooter G, Samyn C, Kinget R (1993) Azo polymers for colon-specific drug delivery. II: Influence of the type of azo polymer on the degradation by intestinal microflora. Int J Pharm 97:133-139
179. van Santen E, Barends DM, Frijlink HW (2002) Breaking of scored tablets: a review. Eur J Pharm Biopharm 53:139-145
180. Vandelli MA, Leo E, Forni F, Bernabei MT (1996) In vitro evaluation of a potential colonic delivery system that releases drug after controllable lag-time. Eur J Pharm Biopharm 43: 148-151
181. Varum FJ, McConnell EL, Sousa JJ, Veiga F, Basit AW (2008) Mucoadhesion and the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 25:207-258
182. Verma RK, Krishna DV, Garg S (2002) Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Control Release 79:7-27
183. Verma RK, Mishra B, Garg S (2000) Osmotically controlled oral drug delivery. Drug Dev Ind Pharm 26:695-708
184. Vervoort L, Kinget R (1996) In vitro degradation by colonic bacteria of inulinHP incorporated in Eudragit RS films. Int J Pharm 129:185-190
185. Volkheimer G (1974) Passage of particles through the wall of the gastrointestinal tract. Environ Health Perspect 9:215-225
186. Walter E, Kissel T, Amidon GL (1996) The intestinal peptide carrier: a potential transport system for small peptide derived drugs. Adv Drug Deliv Rev 20:33-58
187. Walter SIE, De Vries JX, Nickel B, Stenzhorn G, Weber E (1989) The influence of different formula diets and different pharmaceutical formulations on the systemic bioavailabilty of paracetamol, gall bladder size and plasma glucose. Int J Clin Pharmacol Exp Ther Toxicol 27:544-550
188. Washington N, Washington C, Wilson CG (2002) Physiological pharmaceutics: barriers to drug absorption. Taylor & Francis, London
189. Waterman KC (2007) A critical review of gastric retentive controlled drug delivery. Pharm Dev Technol 12:1-10
190. Weissenboeck A, Bogner E, Wirth M, Gabor F (2004) Binding and uptake of wheat germ agglutinin-decorated PLGA-nanospheres by Caco-2 monolayers. Pharm Res 21:1919-1925
191. Weitschies W, Kosch O, Moennikes H, Trahms L (2005) Magnetic marker monitoring: an application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behaviour of magnetically marked solid dosage forms. Adv Drug Deliv Rev 57:1210-1222
192. Whitehead K, Karr N, Mitragotri S (2008) Safe and effective permeation enhancers for oral drug delivery. Pharm Res 25:1782-1788
193. Wirth M, Kneuer C, Lehr CM, Gabor F (2002) Lectin-mediated drug delivery: discrimination between cytoadhesion and cytoinvasion and evidence for lysosomal accumulation of wheat germ agglutinin in the Caco-2 model. J Drug Target 10:439-448
194. Wiwattanapatapee R, Lomlim L, Saramunee K (2003) Dendrimer conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release 88:1-9
195. Wu W, Nancollas GH (1998) A new understanding of the relationship between solubility and particle size. J Solution Chem 27:521-531
196. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, Chen C, Thompson K, Higgins R, Batra U, Shelukar S, Kwei G, Storey D (2004) The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 285:135-146
197. Yang L, Eshraghi J, Fassihi R (1999) A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J Control Release 57:215-222
198. Yeh PY, Berenson MM, Samowitz WS, Kopečková P, Kopecek J (1995) Site-specific drug delivery and penetration enhancement in the gastrointestinal tract. J Control Release 36:109-124
199. Yoshioka M, Hancock BC, Zografi G (1994) Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 83:1700-1705
200. Yoshioka M, Hancock BC, Zografi G (1995) Inhibition of indomethacin crystallization in poly (vinylpyrrolidone) coprecipitates. J Pharm Sci 84:983-986
201. Zentner GM, Rork GS, Himmelstein KJ (1985) The controlled porosity osmotic pump. J Control Release 1:269-282
202. Zhang H, Alsarra IA, Neau SH (2002) An in vitro evaluation of a chitosan-containing multiparticulate system for macromolecule delivery to the colon. Int J Pharm 239:197-205